All In Biotech

Drug Trial Radar · NCT03193190

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 341 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

341

Actual

Start

Jul 5, 2017

Primary completion

Feb 27, 2025

Study completion Feb 27, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

  • Nab-PaclitaxelDrug

    Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

  • GemcitabineDrug

    Gemcitabine will be administered as per the schedule specified in the respective arm.

  • OxaliplatinDrug

    Oxaliplatin will be administered as per the schedule specified in the respective arm.

  • LeucovorinDrug

    Leucovorin will be administered as per the schedule specified in the respective arm.

  • FluorouracilDrug

    Fluorouracil will be administered as per the schedule specified in the respective arm.

  • AtezolizumabDrug

    Atezolizumab will be administered as per the schedule specified in the respective arm.

  • CobimetinibDrug

    Cobimetinib will be administered as per the schedule specified in the respective arm.

  • PEGPH20Drug

    PEGPH20 will be administered as per the schedule specified in the respective arm.

  • BL-8040Drug

    BL-8040 will be administered as per the schedule specified in the respective arm.

  • SelicrelumabDrug

    Selicrelumab will be administered as per the schedule specified in the respective arm.

  • BevacizumabDrug

    Bevacizumab will be administered as per the schedule specified in the respective arm.

  • RO6874281Drug

    RO6874281 will be administered as per the schedule specified in the respective arm

  • AB928Drug

    AB928 will be administered as per the schedule specified in the respective arm.

  • TiragolumabDrug

    Tiragolumab will be administered as per the schedule specified in the respective arm.

  • TocilizumabDrug

    Tocilizumab will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to 33.3 months

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Helen Diller Fam Comp Can Ctr

    San Francisco, California

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Lombardi Cancer Center, Georgetown University

    Washington D.C., District of Columbia

  • Uni of Chicago Medical Center

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • MorristownMedicalCenter

    Morristown, New Jersey

  • Columbia University

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Oregon Health and Science University

    Portland, Oregon

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Universitätsklinikum Essen

    Essen, Germany

  • National Cancer Center Hospital East

    Chiba, Japan

  • Kanagawa Cancer Center

    Kanagawa, Japan

  • National Cancer Center Hospital

    Tokyo, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Universitario Vall d Hebron

    Barcelona, Spain

  • Hosp. G. U Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.